Furthermore, GEN1046 induced significant increases in the percentages of central memory and PD-1+ CD8+ and CD4+ T cells and tumor-specific CD8+ T cells compared with the isotype control and the durvalumab analogue (Fig. 2H). This evidence concerns the gene CD4 and neoplasm.